Kuzmin A I, Tskitishvili O V, Serebryakova L I, Kapelko V I, Majorova I V, Medvedev O S
Institute of Experimental Cardiology, Moscow State University, Russia.
J Cardiovasc Pharmacol. 1995 Apr;25(4):564-71.
With microdialysis, we monitored cardiac interstitial fluid (ISF) levels of allopurinol, its metabolites, and the adenine nucleotide breakdown products (ANBP), inosine, hypoxanthine (HYP), xanthine (Xa), uric acid (UA) in dogs that received 1 and 10 mg/kg allopurinol intravenously (i.v.). Half-life (t1/2) of drug penetration into the heart was dose independent (1.8 min), whereas for the 10-mg/kg dose terminal elimination t1/2 (96 min) was much prolonged and ISF clearance (9.6 l/min kg) was reduced as compared with that induced by 1 mg/kg (28 min and 30.4 l/min kg) probably due to capacity limitation of allopurinol conversion to oxypurinol by Xa dehydrogenase/oxydase (Xa D/O). Inhibition of Xa D/O activity by allopurinol resulted in a dose-dependent increase in ISF HYP and Xa levels and a decrease in UA level. For a 10-mg/kg dose, maximal effect was attained approximately 40 min after drug injection. Allopurinol (1 mg/kg) given 30 min after the start of 40-min coronary artery occlusion during ischemia entered the ischemic zone ISF very slowly as compared with that of the control zone; the no-reflow phenomenon was evident because the levels became similar in both zones only 15 min after initiation of reperfusion. To examine cardioprotective efficiency, we administered allopurinol (10 mg/kg) 40 min before 40-min occlusion; it had little effect on total ANBP release during ischemia but facilitated washout of ANBP from the ischemic zone during reperfusion, thus manifesting protective efficacy against reperfusion injury and no-reflow. As shown by the lack of ischemia-induced increase in ISF Xa, myocardial Xa D/O activity was completely blocked by allopurinol.
采用微透析技术,我们监测了静脉注射(i.v.)1毫克/千克和10毫克/千克别嘌醇的犬心脏间质液(ISF)中别嘌醇、其代谢产物以及腺嘌呤核苷酸分解产物(ANBP)、肌苷、次黄嘌呤(HYP)、黄嘌呤(Xa)、尿酸(UA)的水平。药物渗透到心脏的半衰期(t1/2)与剂量无关(1.8分钟),而对于10毫克/千克剂量,终末消除t1/2(96分钟)明显延长,与1毫克/千克剂量(28分钟和30.4升/分钟·千克)相比,ISF清除率(9.6升/分钟·千克)降低,这可能是由于黄嘌呤脱氢酶/氧化酶(Xa D/O)将别嘌醇转化为氧嘌呤醇的能力受限。别嘌醇对Xa D/O活性的抑制导致ISF中HYP和Xa水平呈剂量依赖性增加,UA水平降低。对于10毫克/千克剂量,在药物注射后约40分钟达到最大效应。在缺血40分钟期间开始30分钟后给予别嘌醇(1毫克/千克),与对照区相比,其进入缺血区ISF的速度非常缓慢;无复流现象明显,因为仅在再灌注开始15分钟后两个区域的水平才变得相似。为了检查心脏保护效率,我们在40分钟闭塞前40分钟给予别嘌醇(10毫克/千克);它对缺血期间总ANBP释放影响不大,但促进了再灌注期间ANBP从缺血区的清除,从而表现出对再灌注损伤和无复流的保护作用。如ISF中Xa缺乏缺血诱导的增加所示,心肌Xa D/O活性被别嘌醇完全阻断。